PURPOSE: This study examines methylprednisolone (MPL) effects on the dynamics of hepatic low-density lipoprotein receptor (LDLR) mRNA and plasma lipids associated with increased risks for atherosclerosis. MATERIALS AND METHODS: Normal male Wistar rats were given 50 mg/kg MPL intramuscularly (IM) and sacrificed at various times. Measurements included plasma MPL and CST, hepatic glucocorticoid receptor (GR) mRNA, cytosolic GR density and hepatic LDLR mRNA, and plasma total cholesterol (TC), low-density lipoprotein cholesterol (LDLC), high density lipoprotein cholesterol (HDLC), and triglycerides (TG). RESULTS: MPL showed bi-exponential disposition with two first-order absorption components. Hepatic GR and LDLR mRNA exhibited circadian patterns which were disrupted by MPL. Down-regulation in GR mRNA (40-50%) was followed by a delayed rebound phase. LDLR mRNA exhibited transient down-regulation (60-70%). Cytosolic GR density was significantly suppressed but returned to baseline by 72 h. Plasma TC and LDLC showed increases (55 and 142%) at 12 h. A mechanistic receptor/gene pharmacokinetic/pharmacodynamic model was developed to describe CS effects on hepatic LDLR mRNA and plasma cholesterols. CONCLUSIONS: Our PK/PD model was able to satisfactorily capture the MPL effects on hepatic LDLR, its relationship to various plasma cholesterols, and builds the foundation to explore this area in the future.
PURPOSE: This study examines methylprednisolone (MPL) effects on the dynamics of hepatic low-density lipoprotein receptor (LDLR) mRNA and plasma lipids associated with increased risks for atherosclerosis. MATERIALS AND METHODS: Normal male Wistar rats were given 50 mg/kg MPL intramuscularly (IM) and sacrificed at various times. Measurements included plasma MPL and CST, hepatic glucocorticoid receptor (GR) mRNA, cytosolic GR density and hepatic LDLR mRNA, and plasma total cholesterol (TC), low-density lipoprotein cholesterol (LDLC), high density lipoprotein cholesterol (HDLC), and triglycerides (TG). RESULTS: MPL showed bi-exponential disposition with two first-order absorption components. Hepatic GR and LDLR mRNA exhibited circadian patterns which were disrupted by MPL. Down-regulation in GR mRNA (40-50%) was followed by a delayed rebound phase. LDLR mRNA exhibited transient down-regulation (60-70%). Cytosolic GR density was significantly suppressed but returned to baseline by 72 h. Plasma TC and LDLC showed increases (55 and 142%) at 12 h. A mechanistic receptor/gene pharmacokinetic/pharmacodynamic model was developed to describe CS effects on hepatic LDLR mRNA and plasma cholesterols. CONCLUSIONS: Our PK/PD model was able to satisfactorily capture the MPL effects on hepatic LDLR, its relationship to various plasma cholesterols, and builds the foundation to explore this area in the future.
Authors: Richard R Almon; Josephine Chen; Grayson Snyder; Debra C DuBois; William J Jusko; Eric P Hoffman Journal: Pharmacogenomics Date: 2003-11 Impact factor: 2.533
Authors: Rohini Ramakrishnan; Debra C DuBois; Richard R Almon; Nancy A Pyszczynski; William J Jusko Journal: J Pharmacokinet Pharmacodyn Date: 2002-02 Impact factor: 2.745
Authors: Vivaswath S Ayyar; Richard R Almon; Debra C DuBois; Siddharth Sukumaran; Jun Qu; William J Jusko Journal: J Proteomics Date: 2017-03-14 Impact factor: 4.044
Authors: Kubra Kamisoglu; Siddharth Sukumaran; Eslam Nouri-Nigjeh; Chengjian Tu; Jun Li; Xiaomeng Shen; Xiaotao Duan; Jun Qu; Richard R Almon; Debra C DuBois; William J Jusko; Ioannis P Androulakis Journal: OMICS Date: 2015-01-22
Authors: Justin C Earp; Debra C Dubois; Diana S Molano; Nancy A Pyszczynski; Richard R Almon; William J Jusko Journal: J Pharmacol Exp Ther Date: 2008-04-30 Impact factor: 4.030
Authors: Justin C Earp; Debra C Dubois; Diana S Molano; Nancy A Pyszczynski; Craig E Keller; Richard R Almon; William J Jusko Journal: J Pharmacol Exp Ther Date: 2008-04-30 Impact factor: 4.030
Authors: Richard R Almon; Debra C Dubois; Siddharth Sukumaran; Xi Wang; Bai Xue; Jing Nie; William J Jusko Journal: Gene Regul Syst Bio Date: 2012-11-28